Nuvation Bio Inc. NUVB
4.19 USD -0.54 (-11.42%)
At closeNov 5, 2026, 7:47 PM EST
4.12 -0.07 -1.67%
After hours · Nov 5, 7:47 PM ET
4.18 Day range 4.81
4.05 52-week range 9.75
- YTD
- -53.24%
- 1 year
- -14.84%
- Market cap
- 1.47B
- Revenue (ttm)
- 169.90M
- Profit margin
- -88.19%
- EPS (ttm)
- -0.44
- Shares out
- 350.12M
- Forward P/E
- -315.00
- YTD return
- -53.24%
- 1-year return
- -14.84%
- Volume
- 8.42M
- Avg volume
- 5.38M
- Open
- 4.46
- Previous close
- 4.73
- Day's range
- 4.18 – 4.81
- 52-week range
- 4.05 – 9.75
- Beta
- 1.73
- Analysts
- Strong Buy
- Price target
- 13.00 (+210.3%)
- Earnings date
- Mar 1, 2027
2Y +1.67 (+65.75%)
Key statistics
- Enterprise value
- 1.40B
- PEG ratio
- 0.00
- Price / sales
- 9.76
- Price / book
- 6.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 555.60%
- Free cash flow
- -112.11M
- Total cash
- 660.96M
- Total debt
- 416.26M
- Return on equity
- -47.81%
- Short % of float
- 29.65%
- 50-day average
- 5.55
- 200-day average
- 5.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +210.3% upside
Now 4.19
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 21.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.10333.
Financials — quick view
NUVB Revenue — quarterly 31.69M
NUVB Net income — quarterly -62.84M
NUVB EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.10 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.12357 | -0.12 | 0.00 | +2.89% |
| Aug 6, 2026 | Jun 30, 2026 | -0.14166 | -0.15 | -0.01 | -5.89% |
| May 4, 2026 | Mar 31, 2026 | -0.02804 | 0.01 | +0.04 | +135.66% |
| Mar 2, 2026 | Dec 31, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Nov 3, 2025 | Sep 30, 2025 | -0.17 | -0.16 | +0.01 | +5.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 16, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 21, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 18, 2026 | JP Morgan | init | — | Overweight |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvationbio.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session 
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17 
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript 
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates 
Nuvation Bio Q3 2026 Earnings Call Transcript 
Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate 
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting 
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting 
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Your note
Sign in to keep a note on NUVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANLEY DAVID C | Chief Technology Officer | Sale | Nov 18, 2025 | 24,000 |
| HUNG DAVID T | Chief Executive Officer | Purchase | Jun 15, 2025 | 59,281,100 |
| LIU DONGFANG | Officer | Sale | Apr 16, 2026 | 18,000 |
| MAKUNJE MOSES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,137 |
| MARKEL STACY | Officer | Sale | Jun 22, 2026 | 32,591 |
| MASHAL ROBERT | Director | Purchase | Jun 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.88% | 52,230,295 | 246.79M | Jun 29, 2026 |
| Blackrock Inc. | 7.87% | 27,630,837 | 130.56M | Jun 29, 2026 |
| Decheng Capital LLC | 7.39% | 25,954,439 | 122.63M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 11,919,514 | 56.32M | Jun 29, 2026 |
| Omega Fund Management, Llc | 2.30% | 8,081,089 | 38.18M | Jun 29, 2026 |
| Laurion Capital Management, LP | 2.19% | 7,697,272 | 36.37M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.04% | 17,697,414 | 83.62M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 8,849,329 | 41.81M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.86% | 6,523,172 | 30.82M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.42% | 4,985,277 | 23.56M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.30% | 4,561,397 | 21.55M | Aug 30, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.98% | 3,423,823 | 16.18M | Sep 29, 2026 |